Cargando…
Periodontal disease in a patient receiving Bevacizumab: a case report
INTRODUCTION: Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bev...
Autores principales: | Gujral, Dorothy M, Bhattacharyya, Sanjeev, Hargreaves, Peter, Middleton, Gary W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2262909/ https://www.ncbi.nlm.nih.gov/pubmed/18271967 http://dx.doi.org/10.1186/1752-1947-2-47 |
Ejemplares similares
-
Metastatic rectal adenocarcinoma within haemorrhoids: a case report
por: Gujral, Dorothy M, et al.
Publicado: (2008) -
Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report
por: Quattrocchi, Carlo C, et al.
Publicado: (2011) -
Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020) -
Extraosseous aneurysmal cyst in hand: a case report
por: Sahu, Ajay, et al.
Publicado: (2008) -
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
por: Liu, Yanxin, et al.
Publicado: (2023)